TSX-V:WAVE - TSX Venture Exchange - CA94357L1058 - Common Stock - Currency: CAD
TSX-V:WAVE (6/3/2025, 7:00:00 PM)
0.02
0 (0%)
The current stock price of WAVE.CA is 0.02 CAD. In the past month the price increased by 33.33%. In the past year, price decreased by -33.33%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 325.64M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 239.50M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 190.36M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 161.85M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 71.18M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 18.23 | 64.99M | ||
BLU.CA | BLUENERGIES LTD | N/A | 59.60M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 57.19M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 48.78M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 44.58M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 43.52M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 30.5 | 42.94M |
Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2017-04-27. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. The company has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.
WAVERLEY PHARMA INC
4-1250 Waverley Street
Winnipeg MANITOBA R3T 6C6 CA
CEO: Larry Thiessen
Employees: 0
Phone: 12049287907
The current stock price of WAVE.CA is 0.02 CAD.
The exchange symbol of WAVERLEY PHARMA INC is WAVE and it is listed on the TSX Venture Exchange exchange.
WAVE.CA stock is listed on the TSX Venture Exchange exchange.
WAVERLEY PHARMA INC (WAVE.CA) has a market capitalization of 1.08M CAD. This makes WAVE.CA a Nano Cap stock.
WAVERLEY PHARMA INC (WAVE.CA) currently has 0 employees.
WAVERLEY PHARMA INC (WAVE.CA) has a support level at 0.01 and a resistance level at 0.02. Check the full technical report for a detailed analysis of WAVE.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
WAVE.CA does not pay a dividend.
WAVERLEY PHARMA INC (WAVE.CA) will report earnings on 2025-08-25.
WAVERLEY PHARMA INC (WAVE.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).
ChartMill assigns a technical rating of 6 / 10 to WAVE.CA. When comparing the yearly performance of all stocks, WAVE.CA is one of the better performing stocks in the market, outperforming 85.98% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to WAVE.CA. WAVE.CA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months WAVE.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 57.28% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -46.29% | ||
ROE | N/A | ||
Debt/Equity | N/A |